Group 1 - The core viewpoint of the news is that Xintiandi Pharmaceutical Co., Ltd. has shown fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks [1][2]. Group 2 - On January 26, Xintiandi's stock rose by 1.39%, with a trading volume of 68.41 million yuan. The margin trading data shows a net buying of 2.13 million yuan for that day [1]. - As of January 26, the total margin trading balance for Xintiandi was 95.42 million yuan, which is 1.86% of its market capitalization and below the 50th percentile level over the past year, indicating a low level of margin financing [1]. - In terms of short selling, on January 26, Xintiandi had no shares sold short, with a short selling balance of 0.00 yuan, which is at a high level compared to the 80th percentile over the past year [1]. Group 3 - As of December 19, the number of shareholders for Xintiandi was 17,900, a decrease of 2.02% from the previous period, while the average circulating shares per person increased by 2.06% to 21,856 shares [2]. - For the period from January to September 2025, Xintiandi reported a revenue of 481 million yuan, a year-on-year decrease of 10.42%, and a net profit attributable to shareholders of 91.90 million yuan, down 35.19% year-on-year [2]. - Since its A-share listing, Xintiandi has distributed a total of 259 million yuan in dividends [2].
新天地1月26日获融资买入831.49万元，融资余额9541.66万元